Table 1

B cells and CD4+ T cells but not CD8+ T cells are needed for successful adoptive immunotherapy of LCMV-WE carrier mice

Exp.Transferred lymphocytesDays after transferVirus titer
BloodBrainSpleenKidney
1d60 immune cells20<1.8<1.9<2.14.8
d8 immune cells202.6 ± 0.64.5 ± 0.64.4 ± 0.35.8 ± 0.2
None6.9 ± 0.36.2 ± 0.26.0 ± 0.37.1 ± 0.4
d60 immune cells
2anti-CD8 + C′ treated90<1.8<1.8<2.23.4 ± 0.3
anti-CD4 + C′ treated905.7 ± 0.14.6 ± 0.35.6 ± 0.36.6 ± 0.2
anti-B cell + C′ treated904.2 ± 0.35.1 ± 0.45.3 ± 0.46.3 ± 0.3
3CD8 depleted40<1.7<2.0<2.04.4 ± 0.2
CD4 depleted402.3 ± 0.62.5 ±0.33.5 ± 0.75.3 ± 0.2
4CD4+ plus CD8+ cells404.6 ± 0.15.5 ± 0.16.5 ± 0.16.8 ± 0.1
CD8+ plus B cells403.8 ± 0.44.7 ± 0.15.7 ± 1.15.9 ± 0.1
CD4+ plus B cells40<1.7<2.0<2.14.5 ± 0.3
  • C57BL/6 mice were infected i.v. with 200 pfu of LCMV-WE. Spleen cells (108) of these mice were taken either 8 days (d8 immune cells) or 60 days after infection (d60 immune cells), and cells were adoptively transferred to C57BL/6 LCMV-WE-infected carrier mice. 

  •  Virus titers are expressed as plaque-forming units per gram of organ or per milliliter of blood (log10 + SEM) and are means ± sem of four mice. Experiments were repeated at least twice with similar results. In experiment (Exp.) 2, either CD4+ or CD8+ T cells or B cells were depleted with mAbs and complement. In experiment 3, CD4+ or CD8+ T cells were depleted with the use of magnetic beads. Cell depletion efficacy was >95%. In experiment 4, CD4+ T cells, CD8+ T cells, and B cells were purified by magnetic beads. Then, 5 × 106 CD4+ T cells, 5 × 106 CD8+ T cells, and 1 × 107 B cells (previously determined as minimally necessary numbers of cells) were injected in various combinations into LCMV-WE carriers. The purity of the enriched spleen cell populations was >95% for B and CD4+ T cells and 80–85% for CD8+ T cells.